Amgen has received EC approval for Aranesp and Neulasta as oncology therapies. The European Commission (EC) has approved both darbepoetin alfa (Aranesp/Nespo for the treatment of anaemia in adult cancer patients with solid tumours (non- haematological malignancies) receiving chemotherapy, and pegfilgrastim (Neulasta/Neupopeg) for the reduction in the duration of neutropenia and the incidence of febrile Read more about Amgen Receives EC Approval[…]